Kathryn Haviland
Chief Executive Officer bei BLUEPRINT MEDICINES CORPORATION
Vermögen: 15 Mio $ am 31.03.2024
Profil
Kathryn Haviland ist Mitglied des Vorstands von Fulcrum Therapeutics, Inc. und Chief Operating Officer bei Blueprint Medicines Corp. sowie Mitglied der Harvard Business School Health Industry Alumni Association und Mitglied des Biopharma Executive Council. Frau Haviland hatte zuvor die Position des Vice President-Rare Diseases bei Idera Pharmaceuticals, Inc. inne, Head-Commercial Development bei Sarepta Therapeutics, Inc. und Executive Director-Commercial Development bei PTC Therapeutics, Inc. Sie erhielt einen Undergraduate-Abschluss von der Wesleyan University und einen MBA von der Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.03.2024 | 153 177 ( 0,25% ) | 15 Mio $ | 31.03.2024 | |
| 27.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Kathryn Haviland
| Unternehmen | Position | Beginn |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Executive Officer | 04.04.2022 |
| FULCRUM THERAPEUTICS, INC. | Chairman | 10.01.2022 |
| Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 16.10.2023 |
Ehemalige bekannte Positionen von Kathryn Haviland
| Unternehmen | Position | Ende |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01.12.2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2012 |
Ausbildung von Kathryn Haviland
| Wesleyan University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
| Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
